

Inflation Reduction Act

Reforming prescription drug prices in the Medicare program is a focal point of the Inflation Reduction Act of 2022 (IRA), signed into law on August 16, 2022.

The IRA's prescription drug pricing provisions include sweeping changes that will impact stakeholders across the health care and life sciences industry.

Among other changes, the IRA's key prescription drug pricing provisions establish the Medicare Drug Price Negotiation Program and the Medicare Prescription Drug Inflation Rebate Program and redesign the Medicare Part D benefit. Manufacturers that fail to comply with applicable IRA provisions could be subject to costly enforcement action.

The IRA's prescription drug pricing provisions will have long-lasting implications for pharmaceutical and biological innovations, and clients look to Epstein Becker Green's IRA team to guide them through the implementation of those provisions and to understand future implications.

How We Help

Epstein Becker Green's IRA team leverages years of experience to provide comprehensive counsel and strategies to advise all players in the drug distribution and payment chain continuum, including drug developers, researchers, biotechnology and pharmaceutical manufacturers, distributors, insurers, pharmacy benefit managers, and pharmacies.

Our IRA team assists our clients in addressing and complying with the operational, compliance, and legal issues that are expected to emerge from the IRA's prescription drug pricing provisions over their multi-year implementation period. We also provide strategic analysis to advise on research and development activities, new product indications, the product approval pathway, launch timing and pricing considerations, operational processes,

Focus Areas

Services

Drug Pricing Policy & Reporting

Contacts



Lynn Shapiro Snyder
Board of Directors / Member of
the Firm
Health Care and Life Sciences
Investor Services
202-861-1806
lsnyder@ebglaw.com

and building infrastructure for compliance. Our deep knowledge in this area stems from advising clients on the spectrum of drug price reporting requirements and compliance obligations, including under Medicare, Medicaid, the 340B Drug Discount program, and other programs.

In the coming months and years, the U.S. Department of Health and Human Services and the Centers for Medicare & Medicaid Services are expected to issue proposed rules and guidance documents relating to the IRA's prescription drug pricing provisions. Our IRA team closely tracks and analyzes new developments in this area to keep clients informed of all critical legal and regulatory updates and to help clients strategically respond to opportunities for comment.

Media

[Game-Changing IRA: Revolutionizing Prescription Drug Pricing and Medicare Benefits](#)

[Inflation Reduction Act's Drug Price Negotiation Provisions – What Now?](#)

[Inflation Reduction Act's Drug Price Negotiation Provisions – What's Next?](#)

[2023 Health Policy Outlook](#)

Insights

[Richard Hughes, Will Walters Quoted in “SCOTUS Cases Could Create ‘Fractured’ Health Care Policy Landscape”
Media Coverage | *AIS Health* | October 20, 2023](#)

[Rachel Snyder Good Featured in “The Top Mid-Law People Moves of 2023 So Far”
Media Coverage | *Law360 Pulse* | July 6, 2023](#)



Constance A. Wilkinson
Board of Directors / Member of
the Firm
Government and Commercial
Coding, Coverage, and Payment
202-861-1378
cwilkinson@ebglaw.com

Team

Alan J. Arville

Alexis Boaz

Spreeha Choudhury

Helaine I. Fingold

Rachel Snyder Good

Philo D. Hall

Richard H. Hughes IV

Stephanie W. Kanwit

Edward M. Kennedy, Jr.

Mark E. Lutes

Leslie V. Norwalk

Christopher R. Smith

James S. Tam

William Walters

Lesley R. Yeung